All
Hospital Group Assails AHIP’s Drug Price Report
April 25th 2023The American Hospital Association said the health insurers' report on drug prices, which highlights the higher prices charged by hospitals, is “a blatant attempt to deflect from the obvious — insurance companies continue to raise premiums for their enrollees and employer clients while pocketing billions in profit.”
Express Scripts Expands Independent Pharmacy in Rural Healthcare
April 20th 2023The expansion offers increased reimbursement opportunities and additional care services to rural independent pharmacies. In addition, it creates an Independent Pharmacy Advisory Committee to expand the role of rural, suburban and urban pharmacies in the healthcare system.
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
April 14th 2023HyQvia is the first FDA-approved treatment for primary immunodeficiency (PI) available as a once-a-month subcutaneous injection. Other treatments for PI, while similarly effective, present a greater burden to patients, often requiring more frequent injections or more invasive routes of administration
New Express Scripts Programs Aim to Boost Affordability, Transparency
April 13th 2023Through Express Scripts’ new Copay Assurance plan, consumers will have lower out-of-pocket costs because of caps on prescription drugs: $5 for generics, $25 for preferred brand drugs, and $45 for preferred specialty brand drugs.
FDA Officially Withdraws Makena, the Only Preterm Birth Med
April 7th 2023Issued jointly by the FDA Commissioner and Chief Scientist, the decision means Makena and its generics are no longer approved and cannot lawfully be distributed in interstate commerce. At the same time, the agency “recognizes that there is a supply of product that has already been distributed.”
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
April 6th 2023The FDA granted the EUA based on the PANAMO phase 3 clinical trial results demonstrating that vilobelimab improved survival compared to placebo, with a 23.9% relative reduction in all-cause mortality at 28 days.